Dr Andrew Wu was previously Chief Operating Officer of Clearbridge Biomedics (now known as Biolidics) where he developed innovative cancer diagnostics technology in the field of liquid biopsy. He was also Chief Product Officer of Clearbridge Health. Both companies are now listed on SGX Catalist. Prior to Clearbridge, Andrew was Technical Director for CordLife, managing the laboratory operations and clinical affairs for the group.
Andrew holds a Bachelors and PhD in Biochemical Engineering from University College London.